| Literature DB >> 21789176 |
Michael Oster1, Eduard Murani, Cornelia C Metges, Siriluck Ponsuksili, Klaus Wimmers.
Abstract
In rodent models and in humans the impact of gestational diets on the offspring's phenotype was shown experimentally and epidemiologically. The underlying programming of fetal development was shown to be associated with an increased risk of degenerative diseases in adulthood, including the metabolic syndrome. There are clues that diet-dependent modifications of the metabolism during fetal life can persist until adulthood. This leads to the hypothesis that the offspring's transcriptomes show short-term and long-term changes depending on the maternal diet. To this end pregnant German landrace gilts were fed either a high protein diet (HP, 30% CP) or an adequate protein diet (AP, 12% CP) throughout pregnancy. Hepatic transcriptome profiles of the offspring were analyzed at prenatal (94 dpc) and postnatal stages (1, 28, 188 dpn). Depending on the gestational dietary exposure, mRNA expression levels of genes related to energy metabolism, N-metabolism, growth factor signaling pathways, lipid metabolism, nucleic acid metabolism and stress/immune response were affected either in a short-term or in a long-term manner. Gene expression profiles at fetal stage 94 dpc were almost unchanged between the diets. The gestational HP diet affected the hepatic expression profiles at prenatal and postnatal stages. The effects encompassed a modulation of the genome in terms of an altered responsiveness of energy and nutrient sensing pathways. Differential expression of genes related to energy production and nutrient utilization contribute to the maintenance of development and growth performance within physiological norms, however the modulation of these pathways may be accompanied by a predisposition for metabolic disturbances up to adult stages.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21789176 PMCID: PMC3138750 DOI: 10.1371/journal.pone.0021691
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Number of regulated probe-sets in liver tissue.
The numbers at the horizontal arrows indicate the quantity of probe-sets significantly regulated between the adjacent ontogenetic stages in either AP or HP offspring, whereas the numbers in the intersections indicate the quantity of probe-sets commonly regulated between stages in AP and HP offspring. The numbers at vertical arrows are the number of probe-sets differentially expressed between AP and HP offspring at the same ontogenetic stage (arrows between boxes show direction of the comparisons; small arrows to top = up-regulated, small arrows to bottom = down-regulated probe-sets).
Significantly regulated transcripts of metabolic pathways in liver tissue within different ontogenetic stages (Ingenuity Pathway Analysis).
| Ontogenetic stage | Regulated pathway | Regulation |
| No. of regulated genes | Genes involved in pathway |
| 94 dpc | - | - | - | - | - |
| 1 dpn | RAN signaling | up | 4.57*E-7 | 6 | IPO5, KPNA3, KPNB1, RAN, RANBP2, TNPO1 |
| Oxidative phosphorylation | down | 2.01*E-15 | 23 | ATP5H, ATP5I, ATP5L, ATP6V0D1, COX6A1, COX6B1, COX6B2, COX7A2, COX7B, COX8A, NDUFA3, NDUFA4, NDUFA13, NDUFB1, NDUFB5, NDUFB6, NDUFB7, NDUFB11, NDUFS7, NDUFS8, SDHB, TCIRG1, UQCR11 | |
| Biosynthesis of steroids | down | 1.19*E-10 | 10 | DHCR7, EBP, FDFT1, FDPS, HMGCR, IDI1, MVK, NQO2, PMVK, SQLE | |
| Val, Leu, Ile degradation | down | 3.41*E-2 | 4 | ACAA1, ACAA2, ACAT2, HMGCS1 | |
| 28 dpn | Val Leu, Ile degradation | down | 6.50*E-4 | 5 | ALDH1A1, ALDH7A1, HADHA, HMGCS1, IVD |
| Fatty acid metabolism | down | 9.55*E-3 | 5 | ACOX1, ALDH1A1, ALDH7A1, HADHA, IVD | |
| 188 dpn | Glucocorticoid receptor signaling | up | 1.75*10-3 | 25 | A2M, AKT3, CD163, FOS, GRB2, GTF2A2, GTF2E2, GTF2F2, HSP90AA1, HSPA8, HSPA9, ICAM1, IL10, JAK1, MAP2K1, MAPK1, MAPK14, PPP3CB, RRAS2, STAT5B, SUMO1, TAF4, TAF7, TAF15, TGFBR2 |
| RAN signaling | up | 8.21*10-3 | 4 | IPO5, KPNA1, KPNA6, RAN | |
| IGF-1 signaling | up | 3.62*10-3 | 12 | AKT3, CSNK2A1, FOS, GRB2, IGF1, MAP2K1, MAPK1, PRKAR1A, RRAS2, YWHAG, YWHAQ, YWHAZ | |
| PPAR signaling | up | 3.82*10-2 | 9 | FOS, GRB2, HSP90AA1, IL18, MAP2K1, MAP4K4, MAPK1, RRAS2, STAT5B | |
| Fatty acid elongation in mitochondria | up | 1.42*10-3 | 5 | ACAA2, HADHB, HSD17B4, PECR, PPT1 | |
| Mitochondrial dysfunction | up | 3.63*10-3 | 12 | AIFM1, APP, CYCS, GLRX2, MAOA, NDUFB3, NDUFB6, NDUFS1, PDHA1, PSEN1, SOD2, UQCRB |
The comparison between the dietary gestational protein levels (HP vs. AP) is shown in dependence of the regulatory direction (up or down).
Significantly regulated transcripts of metabolic pathways in liver tissue between two ontogenetic stages within one dietary group (Ingenuity Pathway Analysis).
| Ontogenetic comparison | Diet | Regulated pathway | Regulation | No. of regulated genes | Genes involved in pathway |
|
| 94 dpc vs. 1 dpn | AP | mTOR signaling | up | 3.42*E-3 | 9 | EIF3I, GNB1L, INSR, MRAS, PRKAA1, PRKCB, RHOG, RHOU, VEGFB |
| AP | RAN signaling | down | 1.43*E-2 | 3 | KPNA6 RANBP2 TNPO1 | |
| HP | Glucocorticoid receptor signaling | up | 4.44*E-3 | 13 | A2M, ERCC3, ESR1, GTF2H3, HMGB1, HSPA1B, MAPK9, PIK3C2A, TAF2, PIK3R1, PIK3R3, PRKACB, PTGES3 | |
| HP | RAN signaling | up | 4.93*E-3 | 3 | CSE1L, KPNA3, TNPO1 | |
| HP | IGF-1 signaling | down | 2.13*E-3 | 6 | FOS, IGFBP3, JUN, PIK3C2B, YWHAB, YWHAE | |
| HP | Biosynthesis of steroids | down | 1.02*E-2 | 3 | DHCR7, MVK, PMVK | |
| HP | Growth hormone signaling | down | 1.33*E-2 | 4 | FOS, IGFBP3, PIK3C2B, SOCS4 | |
| 1 dpn vs. 28 dpn | AP | AMPK Signaling | up | 1.89*E-4 | 9 | AK1, AK7, AKT3, HMGCR, IRS1, MAPK14, PRKAA2, PRKAB2, PRKAG2 |
| AP | Val, Leu, Ile degradation | up | 3.87*E-3 | 5 | ABAT, ACAT1, BCKDHA, HMGCS1, IVD | |
| AP | Oxidative phosphorylation | down | 2.19*E-3 | 8 | ATP6V0E2, ATP7B, COX17, COX10, NDUFA1, NDUFB6, NDUFS8, TCIRG1 | |
| HP | Oxidative phosphorylation | up | 3.70*E-4 | 11 | ATP6V1D, ATP6V1F, ATP6V1H, NDUFA2, NDUFA7, NDUFB1, NDUFB7, NDUFB11, NDUFS3, NDUFS7, TCIRG1 | |
| HP | Growth hormone signaling | up | 1.24*E-2 | 5 | FOS, IGFBP3, PIK3CG, PTPN6, STAT1 | |
| HP | Glucocorticoid receptor signaling | down | 3.12*E-2 | 15 | CDKN1A, JAK2, KRAS, MAP3K7, MNAT1, NCOA1, NR3C1, PCK2, SMAD2, SOS2, TAF5, TAT, TBP, VCAM1 | |
| 28 dpn vs. 188 dpn | AP | Glucocorticoid receptor signaling | down | 1.01*E-2 | 17 | BCL2, GTF2E2, HMGB1, HSPA2, HSPA9, HSPA14, MAP3K1, MAPK14, TBP, NCOA1, NCOR1, PIK3R1, PPP3CA, PRKACB, RAC3, STAT5B, SUMO1 |
| AP | mTOR signaling | down | 2.97*E-2 | 10 | EIF4E, EIF4G2, EIF4G3, PIK3R1, PPP2CA, PPP2CB, PPP2R1B, PRKCB, RAC3, RHOU | |
| AP | RAN Signaling | down | 1.82*E-2 | 3 | CSE1L, RAN, XPO1 | |
| AP | PPAR signaling | down | 3.69*E-2 | 7 | CITED2, MAP4K4, NCOA1, NCOR1, PDGFRA, PPARA, STAT5B | |
| HP | IGF-1 signaling | up | 2.56*E-5 | 11 | AKT3, CTGF, IGF1, IGF1R, IGFBP3, IRS1, PRKAG2, PRKCZ, PTPN11, RRAS2, SOS2 | |
| HP | mTOR signaling | up | 2.73*E-6 | 15 | AKT3, DDIT4, EIF3E, EIF4A2, EIF4B, FNBP1, IRS1, PPP2R5A, PRKAB2, PRKAG2, PRKCZ, RND3, RRAS2, STK11, VEGFA | |
| HP | AMPK signaling | up | 6.87*E-3 | 9 | AKT3, IRS1, PPM1A, PPM1D, PPP2R5A, PRKAB2, PRKAG2, SRC, STK11 | |
| HP | Fatty acid metabolism | up | 9,37*E-3 | 9 | ACAA1, ACADL, ACADSB, ACAT1, AUH, CYP2C18, CYP51A1, IVD, PTGR1 | |
| HP | Val, Leu, Ile degradation | up | 5.89*E-5 | 9 | ACAA1, ACADL, ACADSB, ACAT1, AUH, DBT, HIBCH, IVD, PCCA | |
| HP | Growth hormone signaling | up | 6.03*E-3 | 6 | IGF1, IGF1R, IGFBP3, IRS1, PRKCZ, SOCS6 | |
| HP | Purine metabolism | down | 1.90*E-4 | 17 | ABCC1, AK2, APRT, ATP13A2, BAT1, CANT1, MYO9B, NME1, NSF, PKM2, PNPT1, POLR1E, POLR2G, POLR3G, PRPS2, RRM1, RUVBL2 | |
| HP | Pyrimidine metabolism | down | 1.31*E-2 | 8 | CANT1, DKC1, NME1, PNPT1, POLR1E, POLR2G, POLR3G, RRM1 |
The comparison between dietary gestational protein levels (AP, HP) is shown in dependence of the regulatory direction (up or down).
Figure 2Regulated pathways in liver tissue between ontogenetic stages and maternal diets.
Listed pathways between stages in AP offspring (white boxes) indicate the appropriate ontogenetic development, which doesn't occur in HP offspring (black boxes) at the corresponding developmental period. Pathways between the HP stages indicate processes and metabolic regulations, which occur in the HP offspring but not in the AP offspring in the corresponding developmental period. The differences in gene regulation dependent on diet and ontogenetic stage indicate fetal programming in terms of developmental and metabolic disorders (arrows between boxes show direction of the comparisons; small arrows to top = up-regulated, small arrows to bottom = down-regulated pathways; mTOR, mammalian target of rapamycin; RAN, Ras-related nuclear protein; IGF-1, insulin-like growth factor; PPAR, peroxisome proliferator receptor; AMPK, AMP-activated kinase).
Comparison of microarray data and qRT-PCR of selected transcripts.
| Gene name | Microarray | qRT-PCR | Correlation | ||||
| p-value | FC | Regulation | p-value | FC | Regulation | Expr. values | |
|
| |||||||
| PPARGC1A | 0.0103 | +1.54 | up | 0.012 | +1.63 | up | 0.51 |
| PRKAA2 | 0.0354 | +1.15 | up | 0.007 | +1.47 | up | 0.43 |
| HMGCR | 0.0177 | −1.53 | down | 0.030 | −2.01 | down | 0.84 |
| DHCR7 | 0.0004 | −1.57 | down | 0.001 | −1.76 | down | 0.63 |
| NDUFA4 | 0.0081 | −1.19 | down | 0.310 | −1.15 | n.r. | 0.75 |
| NDUFS7 | 0.0097 | −1.20 | down | 0.480 | −1.14 | n.r. | 0.51 |
| NDUFS8 | 0.0223 | −1.22 | down | 0.030 | −1.32 | down | 0.56 |
|
| |||||||
| PPARGC1A | 0.9341 | +1.01 | n.r. | 0.275 | +1.22 | n.r. | 0.77 |
| PRKAA1 | 0.0083 | −1.35 | down | 0.055 | −1.38 | down | 0.74 |
| GADD45B | 0.0766 | +1.49 | up | 0.047 | +1.81 | up | 0.67 |
calculated by factorial normalization on RPL10 expression values;
p-value of Spearman's rho; n.r. - not regulated.
**p<0.01;
***p<0.001.
Figure 3Experimental design.
Primer used to verify microarray experiments in liver tissue by qRT-PCR.
| Gene name | Probe set ID | Sequence 5′ – 3′ | Accession no. | T( | Size (bp) |
| DHCR7 | Ssc.5455.1.S1_at | For | BE232966 | 60 | 136 |
| GADD45B | Ssc.14764.1.A1_at | For | BF708594 | 60 | 140 |
| HMGCR | Ssc.16088.1.S1_at | For | BP436947 | 60 | 159 |
| NDUFA 4 | Ssc.7315.1.S1_at | For | CF793329 | 60 | 164 |
| NDUFS 7 | Ssc.1681.1.S1_at | For | CK455535 | 60 | 156 |
| NDUFS 8 | Ssc.2312.1.S1_at | For | BI181006 | 60 | 152 |
| PPARGC1A | Ssc.16864.1.S1_at | For | AB106108 | 60 | 208 |
| PRKAA 1 | Ssc.8107.1.A1_at | For | BF712533 | 60 | 193 |
| PRKAA 2 | Ssc.16257.1.S1_at | For | NM214266 | 60 | 168 |
| RPL 10 | Ssc.9130.1.A1_at | For | BI181297 | 60 | 199 |
DHCR7 - 7-dehydrocholesterol reductase; GADD45B - growth arrest and DNA-damage-inducible, beta; HMGCR - 3-hydroxy-3-methylglutaryl-coenzyme A reductase; NDUFA4 - NADH-ubiquinone oxidoreductase MLRQ subunit; NDUFS7 - NADH-ubiquinone oxidoreductase 20 kDa subunit; NDUFS8 - NADH-ubiquinone oxidoreductase 23 kDa subunit; PPARGC1A - Peroxisome proliferator activated receptor gamma coactivator 1 alpha; PRKAA1 – 5′-AMP-activated protein kinase, catalytic alpha-1 chain; PRKAA2 – 5′-AMP-activated protein kinase, catalytic alpha-2 chain; RPL10 - Ribosomal protein 10.
*House keeping gene.